FIGURE 2.

Safety of tixagevimab/cilgavimab for pre-exposure prophylaxis in solid organ transplant recipients (SOTRs). (A) Serum creatinine levels in kidney transplant recipients before and after tixagevimab/cilgavimab administration (n = 92). (B) Alanine aminotransferase (ALT), (C) aspartate aminotransferase (AST), (D) alkaline phosphatase (ALP), and (E) total bilirubin levels in liver transplant recipients after tixagevimab/cilgavimab administration (n = 16). (A) Statistic by paired t-test. (B–E) Statistic by Wilcoxon matched-pairs signed rank test